Actively Recruiting
CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder
Led by University of Arkansas, Fayetteville · Updated on 2026-05-27
76
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of Cannabigerol (CBG) on symptoms associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in adults aged 18 to 55 years. This phase 2 clinical trial aims to determine whether a single dose of CBG can reduce ADHD-related indicators compared to a placebo. Participants will be selected based on symptom severity and other health criteria to ensure safety and relevance. Participants will receive a single dose of either 80mg of Cannabigerol or a placebo, both administered as 1 mL during an experimental session. The placebo is made of MCT oil, while Cannabigerol is a legal, non-high-inducing cannabinoid derived from cannabis. Outcome measures will be collected at 45 minutes and 75 minutes after administration. Participants will also complete daily safety surveys for one week following the dose. Throughout the study, participants will complete several cognitive and attention tasks at 75 minutes post-dose, including the Sustained Attention to Response Task, Trail Making Test, Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, and Iowa Gambling Task. Additional assessments include mood, sleepiness, irritability, pain, anxiety, and global impressions of change. Safety monitoring involves daily surveys for one week after dosing. The total participation duration includes the experimental session plus one week of follow-up.
CONDITIONS
Brief Title
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Between 18 and 55-years-old.
-
BMI between 18 and 35 kg/m2.
-
Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
-
Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
-
Are not pregnant or currently breastfeeding.
-
Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
-
Have not used CBG or any other cannabinoid products in the past 30 days.
-
Willing to abstain from using cannabis or any THC-containing product for the duration of the study.
-
Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).
-
Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.
-
Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.
-
Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.
-
Not currently having thoughts of committing suicide
-
Does not meet criteria for current severe major depressive disorder or a substance use disorder.
-
Have not been diagnosed with bipolar disorder or psychosis.
-
Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).
-
Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).
-
Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.
-
Have access to a ride to the University of Arkansas campus for research appointments.
-
Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).
-
Do not have any serious or unstable physical health conditions including neurological or renal illness.
-
Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.
-
No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit.
-
No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.
-
Not currently prescribed or taking the following medications:
- Warfarin
- Clobazam
- Valproic acid
- Phenobarbital
- Mechanistic Target of Rapamycin [mTOR] Inhibitors
- Oral tacrolimus
- St. John's wort
- Epidiolex
- Escitalopram
- Cardiovascular medications
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
You will not qualify if you...
- Currently pregnant or breastfeeding.
- History of significant allergic conditions or reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
- Use of CBG or any cannabinoid products within the past 30 days.
- Use of synthetic cannabinoids or receptor agonists such as dronabinol, nabilone, spice, or k2.
- Exposure to investigational drugs or devices within 30 days prior to screening or plans to take investigational drugs during the study.
- Changes in current medication use during the study.
- Use of prescription medications for ADHD within the past six months.
- Current suicidal thoughts.
- Diagnosis of severe major depressive disorder or substance use disorder.
- Diagnosis of bipolar disorder or psychosis.
- Presence of acute illness or use of medication for acute illness.
- History of liver disease or significantly impaired liver function.
- Lack of effective contraception use before and after the study.
- No access to transportation for research visits.
- Non-compliance with COVID-19 protocols.
- Serious or unstable physical health conditions including neurological or renal illness.
- Cardiovascular conditions including hypotension, bradycardia, or heart block.
- Detection of atrial fibrillation, bradycardia, or tachycardia during lab visit.
- Recent illicit drug use other than cannabis or alcohol use within 12 hours before lab visit.
- Current use of certain medications such as warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, St. John's wort, Epidiolex, escitalopram, cardiovascular medications, or strong CYP3A4 inhibitors.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single dose of either 80mg Cannabigerol or placebo during an experimental session and undergo cognitive and behavioral assessments.
1 experimental session visit (in-person)
Duration - Up to 75 minutes post administration
Participants complete assessments 45 and 75 minutes after administration to evaluate effects on attention, mood, and other outcomes.
Assessments during the experimental session visit
Trial Site Locations
Total: 1 location
1
University of Arkansas
Fayetteville, Arkansas, United States, 72703
Actively Recruiting
Research Team
E
Ellen W Leen-Feldner, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here